|
gptkbp:instanceOf
|
gptkb:protein
gptkb:drug
erythropoiesis-stimulating agent
|
|
gptkbp:approvedBy
|
1990s
|
|
gptkbp:ATCCode
|
B03XA01
|
|
gptkbp:CASNumber
|
gptkb:113427-24-0
|
|
gptkbp:contraindication
|
uncontrolled hypertension
|
|
gptkbp:developedBy
|
gptkb:Roche
gptkb:Chugai_Pharmaceutical
|
|
gptkbp:hasMolecularFormula
|
C815H1317N233O241S5
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
epoetin beta
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:marketedAs
|
gptkb:Mircera
gptkb:NeoRecormon
|
|
gptkbp:mechanismOfAction
|
stimulates erythropoiesis
|
|
gptkbp:origin
|
recombinant DNA technology
|
|
gptkbp:pregnancyCategory
|
C (US)
|
|
gptkbp:product
|
gptkb:protein
|
|
gptkbp:relatedTo
|
gptkb:darbepoetin_alfa
gptkb:epoetin_alfa
|
|
gptkbp:routeOfAdministration
|
subcutaneous
intravenous
|
|
gptkbp:sideEffect
|
hypertension
thromboembolism
flu-like symptoms
|
|
gptkbp:target
|
erythropoietin receptor
|
|
gptkbp:UNII
|
QGJ0B9WMH2
|
|
gptkbp:usedFor
|
treatment of anemia
anemia due to chronic kidney disease
anemia in cancer patients receiving chemotherapy
|
|
gptkbp:bfsParent
|
gptkb:erythropoietin
|
|
gptkbp:bfsLayer
|
6
|